Antoine Leuzy1, Stephen F Carter2, Konstantinos Chiotis1, Ove Almkvist3, Anders Wall4, Agneta Nordberg5. 1. Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden. 2. Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom. 3. Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden Department of Psychology, Stockholm University, Stockholm, Sweden. 4. Section of Nuclear Medicine and PET, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden. 5. Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Abstract
BACKGROUND: Alzheimer's disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-β1-42 (Aβ1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [(11)C]Pittsburgh compound-B ([(11)C]PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [(11)C]PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. OBJECTIVE: To determine concordance and classification accuracy of CSF biomarkers and [(11)C]PIB PET in a cohort of patients with MCI and AD. METHODS: 68 patients (MCI, n = 33; AD, n = 35) underwent [(11)C]PIB PET and CSF sampling. Cutoffs of >1.41 ([(11)C]PIB), <450 pg/mL-and a more lenient cutoff of 550 pg/mL-(Aβ1-42), <6.5 (Aβ1-42/p-tau181p), and 1.14 (Aβ1-42/t-tau), were used to determine concordance. Logistic regression was used to determine classification accuracy with respect to stable MCI (sMCI) versus MCI who progressed to AD (pMCI). RESULTS: Concordance between [(11)C]PIB and Aβ1-42 was highest for sMCI (67%), followed by AD (60%) and pMCI (33%). Agreement was increased across groups using Aβ1-42 <550 pg/mL, or Aβ1-42 to tau ratios. Logistic regression showed that classification accuracy of [(11)C]PIB, between sMCI and pMCI, was superior to Aβ1-42 (73% versus 58%), Aβ1-42/t-tau (63%), and Aβ1-42/p-tau181p (65%). CONCLUSION: In the present study, [(11)C]PIB proved a better predictor of progression to AD in patients with MCI, relative to CSF measures of Aβ1-42 or Aβ1-42/tau. Discordance between PET and CSF markers for Aβ1-42 suggests they cannot be used interchangeably, as is currently the case.
BACKGROUND:Alzheimer's disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-β1-42 (Aβ1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [(11)C]Pittsburgh compound-B ([(11)C]PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [(11)C]PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. OBJECTIVE: To determine concordance and classification accuracy of CSF biomarkers and [(11)C]PIB PET in a cohort of patients with MCI and AD. METHODS: 68 patients (MCI, n = 33; AD, n = 35) underwent [(11)C]PIB PET and CSF sampling. Cutoffs of >1.41 ([(11)C]PIB), <450 pg/mL-and a more lenient cutoff of 550 pg/mL-(Aβ1-42), <6.5 (Aβ1-42/p-tau181p), and 1.14 (Aβ1-42/t-tau), were used to determine concordance. Logistic regression was used to determine classification accuracy with respect to stable MCI (sMCI) versus MCI who progressed to AD (pMCI). RESULTS: Concordance between [(11)C]PIB and Aβ1-42 was highest for sMCI (67%), followed by AD (60%) and pMCI (33%). Agreement was increased across groups using Aβ1-42 <550 pg/mL, or Aβ1-42 to tau ratios. Logistic regression showed that classification accuracy of [(11)C]PIB, between sMCI and pMCI, was superior to Aβ1-42 (73% versus 58%), Aβ1-42/t-tau (63%), and Aβ1-42/p-tau181p (65%). CONCLUSION: In the present study, [(11)C]PIB proved a better predictor of progression to AD in patients with MCI, relative to CSF measures of Aβ1-42 or Aβ1-42/tau. Discordance between PET and CSF markers for Aβ1-42 suggests they cannot be used interchangeably, as is currently the case.
Authors: Marissa D Zwan; Juha O Rinne; Steen G Hasselbalch; Agneta Nordberg; Alberto Lleó; Sanna-Kaisa Herukka; Hilkka Soininen; Ian Law; Justyna M C Bahl; Stephen F Carter; Juan Fortea; Rafael Blesa; Charlotte E Teunissen; Femke H Bouwman; Bart N M van Berckel; Pieter J Visser Journal: Neurology Date: 2015-10-14 Impact factor: 9.910
Authors: Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin Journal: Cochrane Database Syst Rev Date: 2017-03-22
Authors: Anna H Boerwinkle; Julie K Wisch; Charles D Chen; Brian A Gordon; Omar H Butt; Suzanne E Schindler; Courtney Sutphen; Shaney Flores; Aylin Dincer; Tammie L S Benzinger; Anne M Fagan; John C Morris; Beau M Ances Journal: Neurology Date: 2021-04-30 Impact factor: 11.800
Authors: Antoine Leuzy; Konstantinos Chiotis; Steen G Hasselbalch; Juha O Rinne; Alexandre de Mendonça; Markus Otto; Alberto Lleó; Miguel Castelo-Branco; Isabel Santana; Jarkko Johansson; Sarah Anderl-Straub; Christine A F von Arnim; Ambros Beer; Rafael Blesa; Juan Fortea; Sanna-Kaisa Herukka; Erik Portelius; Josef Pannee; Henrik Zetterberg; Kaj Blennow; Agneta Nordberg Journal: Brain Date: 2016-07-07 Impact factor: 13.501
Authors: Panagiotis Alexopoulos; Lukas Werle; Jennifer Roesler; Nathalie Thierjung; Lena Sophie Gleixner; Igor Yakushev; Nikolaos Laskaris; Stefan Wagenpfeil; Philippos Gourzis; Alexander Kurz; Robert Perneczky Journal: Alzheimers Res Ther Date: 2016-12-09 Impact factor: 6.982
Authors: T A Pascoal; S Mathotaarachchi; S Mohades; A L Benedet; C-O Chung; M Shin; S Wang; T Beaudry; M S Kang; J-P Soucy; A Labbe; S Gauthier; P Rosa-Neto Journal: Mol Psychiatry Date: 2016-03-29 Impact factor: 15.992